An open label balanced randomized single dose two treatment two sequence two period crossover oral bioequivalence study of test formulations of test product 1 plus Alpha Dihydrotetrabenazine plus Alpha DHTBZ 15 mg Powder dissolved in apple juice & test product 2 plus Alpha Dihydrotetrabenazine plus Alpha DHTBZ 15 mg administered as Oral Solution 2 mg per mL Adeptio Pharmaceutical Limited UK in healthy adult human male subjects under fasting conditions - Nil

Start Date17 Aug 2023

Sponsor / Collaborator

Adeptio Pharmaceuticals Ltd.

ACTRN12615001115527

/ Not yet recruitingEarly Phase 1IIT

Randomized, Placebo-Controlled Clinical Trial of Transdermal DHT Gel to Improve IVF Outcomes In Women With Poor Ovarian Response

Start Date04 Jan 2016

Sponsor / Collaborator-

NCT00490022

/ CompletedPhase 1/2IIT

The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men

The purpose of this research study is to understand the effects of a male hormone normally made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under the bladder. The knowledge gained from this study may be used to help in the future to develop a safe male hormonal contraceptive to prevent pregnancy, in the safe treatment of low male hormone levels in men, and in the treatment and prevention of diseases of the prostate.
The investigators will be giving DHT in a gel form, to be applied to the skin, or a placebo gel (with no active drug in it). The investigators want to see the effects of DHT on levels of hormones in the blood and in the prostate gland itself. In addition, the investigators will be studying the effects of DHT on the cells and genes expressed within the prostate.
The effect of DHT on the prostate is not known. Some studies suggest blocking production of DHT in the prostate helps growth of the gland with aging (a condition known as benign prostatic hyperplasia, or BPH for short) and may prevent prostate cancer. On the other hand, DHT administration may shrink the prostate, suggesting it may be beneficial for some men. Therefore, further studies looking at the effect of DHT on the prostate are needed.

Start Date01 Jun 2007

Sponsor / Collaborator

University of Washington

[+2]

100 Clinical Results associated with Androstanolone

100 Translational Medicine associated with Androstanolone

100 Patents (Medical) associated with Androstanolone

18,324

Literatures (Medical) associated with Androstanolone

01 Nov 2025·BIOCHEMICAL PHARMACOLOGY

The CCR5/ROS/NRF2 axis Mediates Dihydrotanshinone I-Induced oxidative stress and apoptosis in hepatocellular carcinoma

Article

Author: Wang, Yining ; Wang, Shusheng ; Gao, Pengfei ; Tu, Ruoxin ; Sun, Lin ; Xu, Ru ; Cai, Jiabin

Despite therapeutic advances, hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide. While dihydrotanshinone I (DHT) shows promising anticancer potential, its molecular mechanisms in HCC remain unexplored. Here, we unveil a novel chemokine (C-C motif) receptor 5 (CCR5)-mediated regulatory network targeted by DHT in HCC treatment. This study identifies CCR5 as a crucial survival factor in HCC, uncovers a novel CCR5-nuclear factor erythroid 2-related factor 2 (NRF2) regulatory axis, and reveals a dual-targeting mechanism of DHT through direct CCR5 inhibition and reactive oxygen species (ROS)-dependent cell death induction, validating its therapeutic efficacy by disrupting redox homeostasis. This work uncovers a novel CCR5-ROS-NRF2 signaling axis in HCC and establishes DHT as a promising therapeutic agent through its unique targeting mechanism. These findings provide new insights into HCC pathogenesis and present an innovative therapeutic strategy for HCC treatment.

01 Oct 2025·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

5α-reductase type 3 is a predictive marker for chemotherapy efficacy in breast cancer in an androgen-independent manner

Article

Author: Miyashita, Minoru ; Ebata, Akiko ; Suzuki, Takashi ; Takagi, Kiyoshi ; Inoue, Naoki ; Sato, Ai ; Yamaguchi-Tanaka, Mio ; Nakamura, Kanoko ; Miki, Yasuhiro

Breast cancer is one of the most representative sex-steroid-dependent cancers and both estrogens and androgens are locally synthesized in breast cancer tissues by sex-steroid producing enzymes. 5α-reductase (5α-Red) is an enzyme which reduces testosterone to biologically active dihydrotestosterone (DHT), serving as a regulator of intratumoral DHT levels. To date, three 5α-Red isozymes have been identified: 5α-Red types 1-3. However, 5α-Red type 3 is not fully examined in breast cancer, and its contribution to DHT synthesis is yet to be elucidated. We therefore immunolocalized 5α-Red type 3 in breast cancer tissues and correlated its immunoreactivity with intratumoral DHT levels as well as clinicopathological parameters. In the present study, 5α-Red type 3 immunoreactivity was not correlated with intratumoral DHT level. Additionally, the immunoreactivity of 5α-Red type 3 was negatively correlated with that of 17β-hydroxysteroid dehydrogenase type 5, which converts androstenedione to testosterone. In the prognostic analysis, although 5α-Red type 3 immunoreactivity was not correlated with patients' clinical outcomes in the entire cohort of 172 breast cancer cases, it was significantly correlated with better clinical outcomes in the patients with non-luminal A type breast cancer or in those who received chemotherapy. These findings suggest that 5α-Red type 3 does not contribute to intratumoral DHT synthesis, while served as a potent predictive marker for efficacy of chemotherapy in breast cancer independent of androgen action.

01 Oct 2025·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Nuclear receptor coactivator 4 linked to follicular dysplasia in polycystic ovary syndrome: A key regulator that aggravates ovarian granulosa cells ferritinophagy and ferroptosis

Article

Author: Wang, Xiaomin ; Weng, Yajing ; Wang, Yong ; Si, Xiaosa ; Zhang, Yaling ; Xu, Ying ; Chen, Dejian ; Wang, Yu ; Liu, Shengbing ; Pan, Weiwei

Ferroptosis is a type of cell death caused by iron-dependent lipid peroxidation and excessive production of reactive oxygen species (ROS). Hyperandrogen exposure can induce ovarian ferroptosis in polycystic ovary syndrome (PCOS). However, there is not enough direct evidence regarding ovarian ferroptosis in PCOS to prove the role of ferroptosis in PCOS and the underlying mechanism. Nuclear receptor coactivator 4 (NCOA4) expression in ovarian granulosa cells and its mechanism of mediating ferroptosis have not been studied. In this study, we aimed to investigate how iron overload in ovarian granulosa cells and hyperandrogen exposure-induced ferroptosis affect ovarian development in a PCOS model. Increased ferroptosis was observed in hyperandrogenic mice with PCOS and in 5α-dihydrotestosterone (DHT)-induced primary granulosa cells. Iron deposition increased significantly, followed by increased cellular Fe²⁺ concentration, whereas ROS accumulation, malondialdehyde (MDA), glutathione (GSH), and the glutathione/oxidized glutathione (GSH/GSSG) ratio decreased. NCOA4 and transferrin receptor expression increased; however, ferritin heavy chain 1 expression decreased in ovarian tissues. Androgen receptor and NCOA4 showed increased colocalization in the ovarian granulosa cell layer. Notably, DHT induced ferroptosis by activating NOCA4-dependent ferritin autophagy. However, deferoxamine mesylate inhibited ferroptosis in the ovarian granulosa mice cells, ameliorating the PCOS phenotype. Steroid hormone biosynthesis, arachidonic acid metabolism, and unsaturated fatty acid pathways were most significantly affected, providing a reference for PCOS diagnosis and treatment and corresponding drug development.

News (Medical) associated with Androstanolone

06 Jun 2025

·www.einpresswire.com

Understanding the Effects of Dihydrotestosterone (DHT) on the Prostate and Treatment Options for Elevated Levels

New Research Highlights DHT’s Role in Prostate Health and Emerging Therapies to Manage Hormone Imbalance Understanding the role of dihydrotestosterone (DHT) is essential for those undergoing testosterone replacement therapy.” — Chris Rue, FNP-C NEW ORLEANS, LA, UNITED STATES, June 6, 2025 / EINPresswire.com / -- Dihydrotestosterone (DHT), a potent androgen derived from testosterone, plays a critical role in the development and maintenance of male characteristics. However, medical experts and researchers are sounding the alarm about its potential impact on prostate health, especially when levels become elevated. DHT is primarily synthesized in the prostate, liver, skin, and hair follicles through the enzymatic conversion of testosterone by 5-alpha reductase. While essential for male development, excessive DHT levels have been strongly linked to benign prostatic hyperplasia (BPH) and an increased risk of prostate enlargement, which can lead to urinary problems and decreased quality of life in aging men. Effects of Elevated DHT on the Prostate: • Prostate Enlargement: Elevated DHT stimulates excessive growth of prostate tissue, contributing to BPH. • Urinary Symptoms: Increased prostate volume can compress the urethra, causing frequent urination, difficulty starting urination, and weak urinary flow. • Potential Cancer Risk: Though the relationship is complex, some studies suggest high DHT levels may influence prostate cancer progression. According to recent clinical reviews, men over the age of 50 are especially vulnerable, with over 50% developing some form of prostate enlargement by age 60. Treatment Options to Lower Elevated DHT Levels: Medical professionals emphasize early intervention and hormone regulation as key strategies. The most common treatments include: 1. 5-Alpha Reductase Inhibitors: Medications such as finasteride (Proscar) and dutasteride (Avodart) block the conversion of testosterone to DHT, reducing prostate size and alleviating symptoms. 2. Natural DHT Blockers: Compounds like saw palmetto extract, pumpkin seed oil, and green tea catechins are under investigation for their mild DHT-lowering effects. 3. Lifestyle Changes: A diet rich in anti-inflammatory foods, regular exercise, and weight management may help regulate hormone levels. 4. Hormonal Monitoring: Regular blood tests to track testosterone and DHT levels can aid in early detection and intervention. Dr. Michael Reynolds, a board-certified urologist, commented, “DHT is essential, but when imbalanced, it can become a catalyst for prostate issues. We now have evidence-based strategies to bring levels back to a healthier range.” About the Prostate Health Initiative The Prostate Health Initiative is a nationwide educational campaign aimed at raising awareness about male hormone balance and its effects on long-term urological health. Through collaboration with healthcare providers and research institutions, the initiative seeks to empower men to make informed choices about their prostate health. ________________________________________ Chris Rue Metairie Optimal Performance Enhancement +1 504-265-5491 info@mopeclinic.com Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

13 Nov 2024

·www.businesswire.com

Havah Therapeutics Granted Additional Patent Protection for T+Ai™

BOULDER, Colo.--( BUSINESS WIRE )--Havah Therapeutics today, announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (US Patent No. 12,128,055) for its innovative T+Ai combination therapy—a novel composition of testosterone and anastrozole in a long-acting, slow-release subcutaneous implant. “Our new patent for T+Ai is a critical milestone as we advance through the ongoing RECAST DCIS Phase 2 trial,” said Matthew Brewer, CEO of Havah Therapeutics. “With a sustained-release profile that shows significant therapeutic promise based on our previous clinical data, we are one step closer to bringing this innovative product to patients.” The newly granted patent for T+Ai further strengthens Havah Therapeutics’ intellectual property portfolio, securing protection for its innovative subcutaneous extended-release therapy. T+Ai was developed to provide a long-term, safe, and well-tolerated solution for hormonal modulation with a particular focus on breast cancer prevention and treatment. This unique formulation of testosterone and anastrozole is designed to address critical needs in oncology, offering potential in the early treatment of estrogen receptor-positive (ER+) cancers to reduce the risk of developing resistance to hormonal therapies. Currently in a Phase 2 platform study, T+Ai’s patented properties include rapid early induction of testosterone conversion to dihydrotestosterone within tissue, potentially enhancing anti-proliferative and anti-cancer effects, especially in women with high mammographic breast density. About Havah Therapeutics Havah Therapeutics is developing a novel therapeutic implant for treating hormonally sensitive cancers and other breast conditions. This groundbreaking method relies on stimulating (agonizing) the androgen receptor in breast tissue, utilizing natural hormonal mechanisms to treat women safely and with greatly reduced side effects. The product, T+Ai™ , is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication enabling a superior product profile for compliance, safety and efficacy. Havah Therapeutics is currently participating in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. For more information, visit www.havahtx.com .

Phase 2

14 May 2024

·www.prnewswire.com

Revian Announces Poster Presentation at 2024 Society for Investigative Dermatology Annual Meeting

Late breaking poster presentation highlights Revian's patented combination of wavelengths has been shown to reduce Dihydrotestosterone production by 74% MORRISVILLE, N.C., May 14, 2024 /PRNewswire/ -- REVIAN Inc., an aesthetic medical technology company using precise wavelengths of LED light to rejuvenate hair and skin, announced an upcoming presentation at the 2024 Society for Investigative Dermatology Annual Meeting being held in Dallas on May 15-18, 2024. Dr. Jacob Kocher will deliver a poster presentation of data illustrating that Revian's patented combination of wavelengths reduces Dihydrotestosterone (DHT) production by 74%, a 95% improvement over industry standard finasteride, which reduced DHT production by 38%, at 24 hours post treatment, in the same in vitro experiment. DHT plays an important causative role in pattern hair loss (androgenic alopecia or pattern baldness). Presentation Details: Poster Title: Inhibition of dihydrotestosterone (DHT) formation via dual wavelength orange-red light production of nitric oxide Category: Translational Studies and Early Preclinical to Clinical Session: Poster only Session Date and Time: May 17th, 4:00-6:00 PM Location: Trinity Exhibit Hall, Hilton Anatole, Dallas "These tests prove Revian's proprietary combination of 620 nm and 660 nm wavelengths block DHT production at a greater rate than the industry standard Finasteride. This is a major breakthrough for hair loss research." stated John Oakley, Chief Executive Officer of Revian. "Having an alternative to a systemic drug with serious side effects is a massive improvement to the available treatment options for anyone seeking a more healthy solution to stopping hair loss." More information on the 2024 Society for Investigative Dermatology Annual Meeting can be found here. About the Revian Red Hair Growth System The REVIAN RED System is an FDA cleared, lightweight wireless cap controlled by a mobile App that functions to provide a hair loss treatment for men and women using precision LED light. The device's patented dual wavelength LED technology provides broader scalp coverage and better skin penetration, producing the best clinical trial performance of any hair rejuvenation treatment available on the market. REVIAN RED uses a patented combination of two wavelengths of light to stimulate the production and release of nitric oxide, which is proven to increase local blood flow, reduce inflammation, and inhibit DHT production. This provides the right environment for new hair growth. REVIAN RED's cleared indication for use is the treatment of androgenetic alopecia, to promote hair growth in males who have Norwood-Hamilton classifications of IIa-V patterns of hair loss and to treat androgenetic alopecia and to promote hair growth in females who have Ludwig-Savin Scale I-1 to II-4, II1, II2 or frontal patterns of hair loss; both with Fitzpatrick Skin Types I-IV. About Revian, Inc. Revian, an operating subsidiary of KNOW Bio, LLC, is an aesthetic medical technology innovator dedicated to stimulating the body's natural processes to rejuvenate hair and skin with light. The company creates products that deliver precise wavelengths of light and allow people to experience its regenerative potential in the convenience of their own homes. Revian is committed to partnering with health-care providers, and other caring professionals, to deliver meaningful results, backed by scientific data. For more information visit . Contact: John Oakley REVIAN, Inc. [email protected] 919-939-7715 SOURCE REVIAN, Inc.

Clinical Result

100 Deals associated with Androstanolone

External Link

KEGG	Wiki	ATC	Drug Bank
D07456	Androstanolone	G03BB02 A14AA01	DB02901

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gynecomastia	-	-	-
Hypogonadism	-	-	-
Scleroderma, Systemic	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low testosterone levels	Phase 2	United States	ASCEND Therapeutics US LLC	01 Oct 2004
Spinocerebellar Degenerations	Phase 2	United States	ASCEND Therapeutics US LLC	01 Oct 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2021	Not Applicable	Penis Agenesis	45	Androstanolone	ludrbdzwtd(jymwcufytn) = omhunlbygp nutzejxiuv (duedhhyxin ) View more	Positive	22 Sep 2021
ESPE2021	Not Applicable	Penis Agenesis	45	Testosterone Enanthate	ludrbdzwtd(jymwcufytn) = zwremivfda nutzejxiuv (duedhhyxin ) View more	Positive	22 Sep 2021
ENDO2021	Not Applicable	DHT \| testosterone (TEST)	14	Dihydrotestosterone (DHT)	mmqmjtfefw(ndaupzcqfb) = DHT mice had a significantly longer estrous cycle length then oil mice qgierssajd (euqqwyiksx ) View more	-	03 May 2021
ESPE2016	Not Applicable	Penis Agenesis SRY \| AR \| SRD5A2	23	Dihydrotestosterone transdermal gel	sapkkytsxl(whwguptsdl) = tbyuuylieq aqjyqcpzzk (axrzcsipow )	Positive	10 Sep 2016
ESPE2015	Not Applicable	testosterone biosynthetic defects	14	Percutaneous DHT gel 0.3-0.4 mg/kg	hvqlmuiaes(ynmpfkjsik) = foouqmuriv rpanxrkumb (qmqxgrqtbq )	Positive	01 Oct 2015
NCT00490022 (DHT-3, CTgov)	Phase 1/2	Inflammation	31	DHT (Placebo DHT Gel)	qflymahhnv(zxydnqyahp) = hzxdtkmcqj zlfgdkdwkm (eaukwgiioi, 0.2) View more	-	09 Jun 2011
NCT00490022 (DHT-3, CTgov)	Phase 1/2	Inflammation	31	DHT (DHT Gel)	qflymahhnv(zxydnqyahp) = owimgldjsm zlfgdkdwkm (eaukwgiioi, 0.5) View more	-	09 Jun 2011
NCT00490022 (Pubmed \| J Clin Endocrinol Metab)	Phase 1/2	-	31	Transdermal DHT gel	mfsunsfitm(gaazaoobdv) = qywqgselxq abdoiyafty (ihytppgkxj )	-	01 Feb 2011
NCT00490022 (Pubmed \| J Clin Endocrinol Metab)	Phase 1/2	-	31	Placebo gel	mfsunsfitm(gaazaoobdv) = venkcvzusu abdoiyafty (ihytppgkxj )	-	01 Feb 2011

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Androstanolone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation